Development and validation of a HPLC method for the determination of voriconazole and its degradation products in pharmaceutical formulation

Acta Pharmaceutica Sciencia

Volumn 52, Issue 2, 2010, Pages 229-238

  Eldin, Ahmed B ^a   Shalaby, Abdalla A ^b   El Maamly, Magda Youssif ^b  

^a SIGMA Corp   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Assay; HPLC; Stability indicating method; Voriconazole

Indexed keywords

ACETONITRILE; DISODIUM HYDROGEN PHOSPHATE; VORICONAZOLE;

ACCURACY; ACIDITY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; LIGHT EXPOSURE; OXIDATION; PH; PHOTODEGRADATION; QUALITY CONTROL; RADIATION DETECTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TABLET FORMULATION; ULTRAVIOLET RADIATION;

EID: 77954197464     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Egle, H., Trittler, R., Koenig, A. and Kuemmerer, K. (2005). A review of determination of voriconazole in human serum. J. Chromatogr. B: Anal Technol. Biomed. Life Sci. 361: 814-816.
2. FDA. (1997). Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms, food and drug administration, Rockville, web site: http://www.fda.gov.
3. Ferretti, R., Gallinella, B., La Torre, F. and Zanitti, L. (1998). A review on determination of voriconazole impurities by HPLC Chromatographia 47: 11-12.
4. Hoffman, H.L. and Rathbun, R.C. (2002). Review of the safety and efficacy of voriconazole. Expert. Opin. Investig. Drugs 11: 409-429.
5. ICH - International Conference on Harmonisation. (2005). Topic Q2B, Validation of Analytical Methods: Methodology. The Third International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Yokohama-Japan. 1.8: 71-76.
6. Keevil, B.G., Newman, S., Lockhart, S., Howard, S.J., Moore, C.B., Denning, D.W. (2004). A review of determination of voriconazole in human serum. Ther. Drug. Monit. 26: 650-655.
7. Miller, J. C. and Miller, J. N. (1993). Limit of detection. Statistics for analytical chemistry. 3rd ed., 233 p.
8. Owens, P.K., Fell, A.F., Coleman, M.W. and Berridge, J.C. (2002). Separation of the voriconazole stereoisomers by capillary electrophoresis and liquid chromatography. Enantiomer 4: 79-90.
9. Pehourcq, F., Jarry, C., Bannwarth, B. (2004). A review of determination of voriconazole in human serum. Biomed. Chromatogr. 18: 719-722.
10. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., Diekema, D.J. (2001). In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida - SENTRY Antimicrobial Surveillance Program. 4: 1032-1039.
11. Pfizer, Inc; New York (2002). VFEND (voriconazole) tablets and injection [package insert].
12. Purkins, L., Wood, N., Gharamani, P., Greenhalgh, K., Allen, M.J. and Kleinermans, D. (2002). A review of determination of voriconazole in human serum. Antimicrob. Agents Chemother. 46: 2546-2550.
13. United States Pharmacopoeia. (2009). Validation of compendia method-Pharmacopeial Forum 32: 1225.
14. Vander, Y., Heyden, A., Nijhuis, J., Smeyers-Verbeke, B.G.M., Vandeginste, D.L. (2007). Talanta. 71: 1424-1429.
15. Zhou, L., Glickman, R.D., Chen, N., Sponsel, W.E., Graybill, J.R., Lam, K.W. (2002). A review of determination of voriconazole in human serum. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 213: 776-778.